Bellvitge University Hospital
Verified site
L'hospitalet De Llobregat, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on adults with Epilepsy that is not controlled by other medicines, specifically focal onset seizures. These are seizures that start in one part of the brain. The investigational drug being examined is called RAP-219, taken as a tablet by mouth.
The main aim is to assess the long‑term safety and how well the medicine is tolerated when used over an extended period. Participants will take the study tablet regularly and will attend scheduled visits where doctors will check blood pressure, heart rhythm using an ECG, and basic blood work, as well as ask about any new symptoms or side effects.
Throughout the study, participants will keep a simple diary of seizure occurrences and will have periodic check‑ups that may include a brief physical exam, blood tests, and the heart rhythm test. The study will continue for many months to gather information on any changes in health and to see if the frequency of seizures changes compared with the start of the study.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
8 criteria
11 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
L'hospitalet De Llobregat, Spain
Coimbra, Portugal
Frankfurt, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.